RS64113B1 - Mesilatna so amino-lupan jedinjenja koja inhibitorno deluje na sazrevanje hiv - Google Patents

Mesilatna so amino-lupan jedinjenja koja inhibitorno deluje na sazrevanje hiv

Info

Publication number
RS64113B1
RS64113B1 RS20230264A RSP20230264A RS64113B1 RS 64113 B1 RS64113 B1 RS 64113B1 RS 20230264 A RS20230264 A RS 20230264A RS P20230264 A RSP20230264 A RS P20230264A RS 64113 B1 RS64113 B1 RS 64113B1
Authority
RS
Serbia
Prior art keywords
lupane
amino
compound
inhibitory activity
mesylate salt
Prior art date
Application number
RS20230264A
Other languages
English (en)
Inventor
Amy Woods
Original Assignee
Viiv Healthcare Uk No 4 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 4 Ltd filed Critical Viiv Healthcare Uk No 4 Ltd
Publication of RS64113B1 publication Critical patent/RS64113B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20230264A 2018-12-10 2019-12-09 Mesilatna so amino-lupan jedinjenja koja inhibitorno deluje na sazrevanje hiv RS64113B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862777432P 2018-12-10 2018-12-10
US201962874557P 2019-07-16 2019-07-16
EP19823817.2A EP3894424B1 (en) 2018-12-10 2019-12-09 Mesylate salt of an amino-lupane compound with hiv maturation inhibitory activity
PCT/IB2019/060564 WO2020121161A1 (en) 2018-12-10 2019-12-09 Mesylate salt of an amino-lupane compound with hiv maturation inhibitory activity

Publications (1)

Publication Number Publication Date
RS64113B1 true RS64113B1 (sr) 2023-04-28

Family

ID=68944386

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230264A RS64113B1 (sr) 2018-12-10 2019-12-09 Mesilatna so amino-lupan jedinjenja koja inhibitorno deluje na sazrevanje hiv

Country Status (14)

Country Link
US (1) US20220024970A1 (sr)
EP (1) EP3894424B1 (sr)
JP (1) JP2022510475A (sr)
DK (1) DK3894424T3 (sr)
ES (1) ES2938486T3 (sr)
FI (1) FI3894424T3 (sr)
HR (1) HRP20230208T1 (sr)
HU (1) HUE061184T2 (sr)
LT (1) LT3894424T (sr)
PL (1) PL3894424T3 (sr)
PT (1) PT3894424T (sr)
RS (1) RS64113B1 (sr)
SI (1) SI3894424T1 (sr)
WO (1) WO2020121161A1 (sr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2013MU01749A (sr) * 2013-05-15 2015-06-26 Cipla Ltd
CA2944778C (en) 2014-04-11 2022-06-14 ViiV Healthcare UK (No.4) Limited Triterpenoids with hiv maturation inhibitory activity

Also Published As

Publication number Publication date
LT3894424T (lt) 2023-03-10
DK3894424T3 (da) 2023-03-06
ES2938486T3 (es) 2023-04-11
EP3894424B1 (en) 2023-01-25
FI3894424T3 (fi) 2023-04-25
JP2022510475A (ja) 2022-01-26
PL3894424T3 (pl) 2023-05-02
EP3894424A1 (en) 2021-10-20
HRP20230208T1 (hr) 2023-04-14
SI3894424T1 (sl) 2023-04-28
PT3894424T (pt) 2023-02-28
WO2020121161A1 (en) 2020-06-18
HUE061184T2 (hu) 2023-05-28
US20220024970A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
EP3691663A4 (en) METHOD OF TREATING IMMUNOTHERAPY ASSOCIATED TOXICITY USING GM-CSF ANTAGONIST
ZA201804943B (en) 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
IL281243A (en) Methods for the treatment of toxicity associated with immunotherapy with the help of a GM-CSF antagonist
IL276592A (en) History of Subtirum
IL290692A (en) Salt
EP3894768C0 (en) METHOD FOR CRYOHARDENING
PL3445766T3 (pl) Nowy związek przeciwdrobnoustrojowy
GB2588505B (en) Preparation of psilocybin
GB2570868B (en) Tackle shield
LT3894424T (lt) Amino-lupano junginio mezilato druska su živ brendimą slopinančiu aktyvumu
PT3784349T (pt) Compostos com atividade inibidora de maturação do hiv
RS61238B1 (sr) Kristal jedinjenja sa inhibitornom aktivnošću prema jak
ZA202105399B (en) Use of spiropidion
IL276195A (en) Salt forms of an organic compound
GB201819757D0 (en) Compounds with antimicrobial activity
IL260405A (en) None-abusive derivatives of ritalin
IL274084A (en) Comb for the treatment of dandruff
GB201917107D0 (en) Process for shelf-life extention of fish
GB201904190D0 (en) Salt
GB201812740D0 (en) Firewall
GB201810835D0 (en) Methods of use
GB201720156D0 (en) Compounds with antimicrobial activity
AU2016900938A0 (en) Activity Pulse